Abstract
The S100A9 protein is an important proinflammatory factor of innate immunity that has been proposed to participate in inflammation associated with the pathogenesis of Alzheimer’s disease. Here, we provide insights into the potential roles of extracellular S100A9 in the interaction with the immune response in human THP-1 monocytic cells that have been challenged with amyloid β1-42 (Aβ1-42) monomers instead of oligomers. Extracellular S100A9 alone produced a stimulatory effect on tumor necrosis factor-α and interleukin-1β, expression as well as released monocyte chemoattractant protein-1 into culture supernatants, which was accompanied by an increased level of matrix metalloproteinas-9 activity. Importantly, co-stimulation with S100A9 and Aβ1-42 resulted in a marked enhancement of Aβ1-42-mediated release of these proinflammatory mediators under the same experimental conditions, whereas heat inactivated S100A9 had little effect. Our findings clearly suggest that excess S100A9 protein may play an important role in the pathological processes of Alzheimer’s disease by exacerbating the Aβ1-42-induced innate immune response.
Keywords: Alzheimer’s disease, innate immunity, S100A9.
CNS & Neurological Disorders - Drug Targets
Title:S100A9 Exacerbates the Aβ1-42-mediated Innate Immunity in Human THP-1 Monocytes
Volume: 15 Issue: 8
Author(s): Kyoung A. Jhang, Eun Ok Lee, Hee-Sun Kim, Keun-A Chang, Yoo-Hun Suh and Young Hae Chong
Affiliation:
Keywords: Alzheimer’s disease, innate immunity, S100A9.
Abstract: The S100A9 protein is an important proinflammatory factor of innate immunity that has been proposed to participate in inflammation associated with the pathogenesis of Alzheimer’s disease. Here, we provide insights into the potential roles of extracellular S100A9 in the interaction with the immune response in human THP-1 monocytic cells that have been challenged with amyloid β1-42 (Aβ1-42) monomers instead of oligomers. Extracellular S100A9 alone produced a stimulatory effect on tumor necrosis factor-α and interleukin-1β, expression as well as released monocyte chemoattractant protein-1 into culture supernatants, which was accompanied by an increased level of matrix metalloproteinas-9 activity. Importantly, co-stimulation with S100A9 and Aβ1-42 resulted in a marked enhancement of Aβ1-42-mediated release of these proinflammatory mediators under the same experimental conditions, whereas heat inactivated S100A9 had little effect. Our findings clearly suggest that excess S100A9 protein may play an important role in the pathological processes of Alzheimer’s disease by exacerbating the Aβ1-42-induced innate immune response.
Export Options
About this article
Cite this article as:
Jhang A. Kyoung, Lee Ok Eun, Kim Hee-Sun, Chang Keun-A, Suh Yoo-Hun and Chong Hae Young, S100A9 Exacerbates the Aβ1-42-mediated Innate Immunity in Human THP-1 Monocytes, CNS & Neurological Disorders - Drug Targets 2016; 15 (8) . https://dx.doi.org/10.2174/1871527315666160815161922
DOI https://dx.doi.org/10.2174/1871527315666160815161922 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Relevance of Aβ 1-42 Intrahippocampal Injection as An Animal Model of Inflamed Alzheimers Disease Brain
Current Alzheimer Research Editorial (Hot Topic: Therapeutic Targets in Neurodegenerative Diseases)
Current Enzyme Inhibition A Genetic Dissection of Antipsychotic Induced Movement Disorders
Current Medicinal Chemistry Pharmacology of the Human Saphenous Vein
Current Vascular Pharmacology Genome-Wide Association Studies: Is there a Genotype for Cognitive Decline in Older Persons with Type 2 Diabetes?
Current Pharmaceutical Design Cognition in Non-Demented Diabetic Older Adults
Current Aging Science Role of Amylin and its Receptors in Neurodegeneration
Current Protein & Peptide Science Novel Risk Factors Related to Stable Angina
Current Pharmaceutical Design Effective Inhibition of Foam Cells Formation by Tanshinone IIA in RAW264.7 Macrophages Induced with LDL Isolated from Hypercholesterolemia Patients: A Proteomic Analysis
Current Proteomics The Applications of Pharmacogenomics to Neurological Disorders
Current Molecular Medicine The Role of PGC-1α in the Pathogenesis of Neurodegenerative Disorders
Current Drug Targets The Chemistry and Biology of the Bryostatins: Potential PKC Inhibitors in Clinical Development
Current Medicinal Chemistry Val17Ile Single Nucleotide Polymorphisms Similarly as Ala15Thr Could be Related to the Lower Secretory Dynamics of PAI-1 Secretion – Theoretical Evidence
Current Molecular Medicine Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Phytochemicals and Antioxidants: An Evaluation in Understanding the Human Lifeline
Current Nutrition & Food Science Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer,s Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Current Alzheimer Research Association Between Polycystic Ovary Syndrome and Metabolic Syndrome
Current Medicinal Chemistry Platelets and Vascular Risk: An Option for Treatment
Current Pharmaceutical Design Gene-Gene and Gene-Environment Interaction on the Risk of Parkinson’s Disease
Current Aging Science A Novel Prescription for Alzheimer’s Disease: Targeting Hypercoagulable States
Current Neurovascular Research